尚会影响血小板激活和血栓形成
Hui Zhu1,2, Ruoyi Shen3, Chenyue Wang1,2
1Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Platelets
|December 16, 2025
概括
赞是一种天然化合物,显著抑制血小板激活和聚合. 这一发现表明,ksanthone.
科学领域:
- 生物化学 生物化学
- 药理学 药理学 是一个学科.
- 血液学 血液学 血液学
背景情况:
- 赞 (Xanthone) 是一种来自Garcinia的化合物,具有多种生物活性.
- 它在血小板功能中的作用在很大程度上仍未被描述.
研究的目的:
- 为了研究香对人类血小板功能的影响.
- 在体内评估桑对血液静止和血栓形成的影响.
主要方法:
- 人类血小板在不同的香度 (020μM) 中进行了化.
- 分析了血小板聚合,颗粒释放,激活,受体表达,扩散和凝块收缩.
- 在体内研究涉及给小鼠施用桑 (10毫克/公斤) 来评估血液静止和血栓形成.
主要成果:
- 克桑剂量取决于降低了血小板聚合和颗粒释放.
- 它抑制了血小板扩散,凝块收缩和关键信号分子 (c-Src,PLCγ2) 的酸化.
- 在体内,香延长了出血时间,并降低了动脉和静脉血栓的发生.
结论:
- 桑通过多种机制损害了血小板激活和血栓形成.
- 它抑制了包括NF-κB,ERK1/2,p38和调动在内的信号通路.
- 克桑显示出作为血栓和心血管疾病的新型治疗剂的潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K


